Capricor Therapeutics Inc’s recent filing unveils that its 10% Owner Nippon Shinyaku Co Ltd acquired Company’s shares for reported $15.0 million on Sep 20 ’24. In the deal valued at $5.36 per share,2,798,507 shares were bought. As a result of this transaction, Nippon Shinyaku Co Ltd now holds 7,090,351 shares worth roughly $90.83 million.
Piper Sandler initiated its Capricor Therapeutics Inc [CAPR] rating to an Overweight in a research note published on October 21, 2024; the price target was $35. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in mid May with a ‘”an Outperform”‘ rating. Cantor Fitzgerald began covering CAPR with “an Overweight” recommendation on January 05, 2024. Ladenburg Thalmann started covering the stock on October 26, 2022. It rated CAPR as “a Buy”.
Price Performance Review of CAPR
On Friday, Capricor Therapeutics Inc [NASDAQ:CAPR] saw its stock fall -5.70% to $12.81. Over the last five days, the stock has lost -16.71%. Capricor Therapeutics Inc shares have fallen nearly -7.17% since the year began. Nevertheless, the stocks have risen 158.53% over the past one year. While a 52-week high of $23.40 was reached on 02/18/25, a 52-week low of $3.52 was recorded on 03/05/25. SMA at 50 days reached $14.32, while 200 days put it at $11.10.
Levels Of Support And Resistance For CAPR Stock
The 24-hour chart illustrates a support level at 12.39, which if violated will result in even more drops to 11.98. On the upside, there is a resistance level at 13.56. A further resistance level may holdings at 14.31. The Relative Strength Index (RSI) on the 14-day chart is 41.32, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.35, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 82.79%. Stochastics %K at 21.86% indicates the stock is a holding.
